2024-04-05 09:12:50
The American Association for Cancer Research will be held from the 5th to the 10th.
Dong-A ST discloses research data for immunotherapy candidate ‘DA-4511’
SHP1, a protein family that reduces immune function
Dong-A ST successfully discovers a small molecule compound that selectively inhibits SHP1
Dong-A ST announced the launch of the SHP1 allosteric inhibitor and immunotherapy candidate ‘DA-4511’ through the ‘American Association for Cancer Research (AACR 2024)’ held in San Diego, California, USA from the 5th (local time) to the 10th. It was announced on the 5th that the preclinical results will be presented on a poster.
AACR is considered one of the world’s top three cancer societies, along with the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO). Cancer research experts and industry officials from around the world gather to share the latest knowledge in the field of anticancer treatment and new drugs.
In the case of Dong-A ST, the academic society introduces the efficacy and safety of DA-4511, a candidate substance being developed as the first new drug in the series. Data on the effect of DA-4511 on increasing cytokine secretion from immune cells and promoting phagocytic function of macrophages will be disclosed. In addition, we plan to announce the anti-cancer effect in animal model tests and the synergy effect through co-administration with the existing immune checkpoint inhibitor PD-1 antibody.
DA-4511 is a SHP1 (Src homology phosphatase-1) inhibitor. SHP1 is known to be a type of protein tyrosine phophatase that reduces immune function by suppressing phosphorylation activation signals in immune cells. Research into SHP1 inhibition is being conducted with the goal of increasing the immune function of immune cells and strengthening the attack function against cancer cells, but it is difficult to develop a selective SHP1 inhibitor due to the structural similarity of the dephosphorylation enzyme active site.
Dong-A ST successfully discovered an allosteric site that can selectively inhibit SHP1 and used it to discover a small molecule compound that can be taken orally. Here, Yonsei University researchers plan to present the anti-cancer effect through combined administration of the aryl hydrocarbon receptor (AhR, Aryl Hydrocarbon Receptor) antagonist ‘DA-4505’ and anti-PD-1 immune checkpoint inhibitor.
A Dong-A ST official said, “In preclinical trials, we confirmed the potential for DA-4511 to be developed as the world’s first SHP1 allosteric inhibitor and a new immuno-anticancer agent, as well as its effects in increasing immune cell cytokine secretion and promoting macrophage phagocytic function,” adding, “We will conduct preclinical trials as soon as possible.” “We will focus our capabilities to complete the research and enter the next stage,” he said.
Kim Min-beom, Donga.com reporter [email protected]
-
- great
- 0dog
-
- I’m so sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog
Hot news now
2024-04-05 09:12:50